Turn Therapeutics
- Country
- Ownership
- -
- Employees
- 2
- Market Cap
- -
- Introduction
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company’s proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Turn Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT04951349
- Locations
- 🇵🇦
Gorgas Memorial Research Hospital, Panama City, Panama
🇵🇦Hospital Modular COVID-19, Panama City, Panama
🇵🇦Hospital Santo Tomas, Panama City, Panama
News
Turn Therapeutics Prepares for Nasdaq Debut with Focus on Dermatology and Infectious Disease Programs
Turn Therapeutics, a clinical-stage biotechnology company, expects to begin trading on Nasdaq Global Market under ticker "TTRX" on October 8, 2025.
Turn Therapeutics Initiates First Clinical Trial of Topical IL-36 Inhibitor GX-03 for Moderate-to-Severe Eczema
Turn Therapeutics has begun a randomized, double-blind, vehicle-controlled clinical trial evaluating topical GX-03 formulation for moderate-to-severe eczema treatment, marking the first clinical trial of a topical IL-36 inhibitor.
Turn Therapeutics Achieves Breakthrough in Room-Temperature Vaccine Stability
Turn Therapeutics has demonstrated 100% recovery of vesicular stomatitis virus (VSV) after 72 hours in an oil-based carrier at room temperature, potentially eliminating cold storage requirements for vaccines.
Turn Therapeutics' GX-03 Shows Promise in Atopic Dermatitis by Inhibiting Key Cytokines
Turn Therapeutics' GX-03 demonstrated significant inhibition of IL-31, IL-36α, and IL-36γ in a preclinical eczema model, suggesting potential efficacy in atopic dermatitis.